Bar Harbor Wealth Management Has $6.62 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Bar Harbor Wealth Management decreased its position in Novo Nordisk A/S (NYSE:NVO) by 34.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 76,999 shares of the company’s stock after selling 39,669 shares during the period. Bar Harbor Wealth Management’s holdings in Novo Nordisk A/S were worth $6,623,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. International Assets Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC grew its position in shares of Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd bought a new position in shares of Novo Nordisk A/S during the third quarter worth approximately $98,765,000. Marshall Wace LLP raised its position in shares of Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after buying an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $42,017,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.1 %

Shares of Novo Nordisk A/S stock traded down $1.83 during trading on Monday, hitting $84.43. The company’s stock had a trading volume of 6,634,506 shares, compared to its average volume of 7,230,714. The stock has a market cap of $378.88 billion, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $81.50 and a 52 week high of $148.15. The stock has a 50-day moving average price of $100.35 and a two-hundred day moving average price of $119.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NVO. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.